Clinical trial No longer in our active list Phase 2 Interventional Ages 18 and up

Investigating a new treatment for Waldenström Macroglobulinemia

Official title: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia

Run by BeiGene · NCT05952037 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new drug called sonrotoclax to see if it can help adults with Waldenström Macroglobulinemia feel better, either on its own or with another medication, especially for those who haven't had success with other treatments.

More Waldenstrom Macroglobulinemia trials Research outlook What's coming for Waldenström macroglobulinemia: the next 6 months to 5 years

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment105 (estimated)
SponsorBeiGene
Industry-sponsored
Drugs / interventionszanubrutinib
Locations72 sites (Duarte, California and 71 other locations)
Trial IDNCT05952037 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults with a confirmed diagnosis of Waldenström Macroglobulinemia, especially those with relapsed or refractory disease or those who have not yet received treatment.

Probably not a fit

Patients with central nervous system involvement by Waldenström Macroglobulinemia or those who have transformed to aggressive lymphoma may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in adults with Waldenström Macroglobulinemia, both as a standalone treatment for those who have not responded to previous therapies and in combination with zanubrutinib for previously untreated patients. The study aims to determine the proportion of participants who achieve cancer remission or experience symptom improvement, as well as to monitor any adverse effects from the treatments. Approximately 105 participants will be enrolled, and the study will take place across multiple centers worldwide over a period of about 5 years.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with Waldenström Macroglobulinemia, particularly those who have not responded to existing therapies.

How similar studies have gone: While the approach of targeting BCL2 proteins is promising, this specific combination treatment is novel and has not been extensively tested in previous studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Clinical and definitive histologic diagnosis of WM.
* Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd International Workshop on Waldenström's Macroglobulinemia (IWWM).
* For Cohorts 1-3, refractory or relapsed disease at study entry unless participants had intolerance to the most recent therapy. Refractory disease is defined as not attaining at least a major response, or progressing while on or within 6 months of completing therapy. Relapsed disease is defined as attaining at least a major response to therapy and meeting the criteria for disease progression beyond 6 months after completing therapy.
* For Cohort 4, patients must not have received prior therapy for WM (except for plasmapheresis).
* Adequate organ function.

Exclusion Criteria:

* Central nervous system (CNS) involvement by WM.
* Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma.
* History of other malignancies ≤ 2 years before study entry.
* Uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy that was completed ≤ 14 days before the first dose of the study drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

  • City of Hope National Medical Center
    Duarte, California, United States
    Recruiting
  • Colorado Blood Cancer Institute
    Denver, Colorado, United States
    Recruiting
  • Medstar Georgetown University Hospital
    Washington, District of Columbia, United States
    Recruiting
  • University of Miami
    Miami, Florida, United States
    Recruiting
  • Northwestern Medicine Cancer Center
    Warrenville, Illinois, United States
    Recruiting
  • Mission Cancer and Blood
    Waukee, Iowa, United States
    Recruiting
Show 44 more locations
  • University of Maryland Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota, United States
    Recruiting
  • Hattiesburg Hematology and Oncology Clinic
    Hattiesburg, Mississippi, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center Mskcc
    New York, New York, United States
    Recruiting
  • Atrium Health Levine Cancer Institute (Lci)
    Charlotte, North Carolina, United States
    Recruiting
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio, United States
    Recruiting
  • Ut Southwestern Medical Center
    Dallas, Texas, United States
    Recruiting
  • Huntsman Cancer Institute
    Salt Lake City, Utah, United States
    Recruiting
  • Virginia Commonwealth University Massey Cancer Center
    Richmond, Virginia, United States
    Recruiting
  • University of Washington
    Seattle, Washington, United States
    Recruiting
  • Concord Repatriation General Hospital
    Concord, New South Wales, Australia
    Recruiting
  • Genesiscare North Shore
    St Leonards, New South Wales, Australia
    Recruiting
  • Princess Alexandra Hospital
    Woolloongabba, Queensland, Australia
    Recruiting
  • Flinders Medical Centre
    Bedford PK, South Australia, Australia
    Recruiting
  • Monash Health
    Clayton, Victoria, Australia
    Recruiting
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria, Australia
    Recruiting
  • Linear Clinical Research
    Nedlands, Western Australia, Australia
    Recruiting
  • Royal Perth Hospital
    Perth, Western Australia, Australia
    Recruiting
  • Cross Cancer Institute
    Edmonton, Alberta, Canada
    Recruiting
  • Lions Gate Hospital Chemotherapy Clinic
    North Vancouver, British Columbia, Canada
    Recruiting
  • Qeii Health Science Center
    Halifax, Nova Scotia, Canada
    Recruiting
  • Princess Margaret Cancer Centre
    Toronto, Ontario, Canada
    Recruiting
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong, China
    Recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
    Recruiting
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
  • Yancheng First Peoples Hospital
    Yancheng, Jiangsu, China
    Recruiting
  • Shengjing Hospital of China Medical Universityshenbei Branch
    Shenyang, Liaoning, China
    Recruiting
  • The Affiliated Hospital of Qingdao University Branch South
    Qingdao, Shandong, China
    Recruiting
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai, China
    Recruiting
  • The Third Peoples Hospital of Datong
    Datong, Shanxi, China
    Recruiting
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin, China
    Recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
  • The First Hospital of Jiaxing
    Jiaxing, Zhejiang, China
    Recruiting
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Recruiting
  • Centre Hospitalier Universitaire Damiens Hopital Sud
    Amiens Cedex, France
    Recruiting
  • Chu Clermont Ferrand Therapie Cellulaire and Hematolo
    Clermontferrand, France
    Recruiting
  • Institut Paoli Calmettes
    Marseille, France
    Recruiting
  • Hopital de La Pitie Salpetriere
    Paris, France
    Recruiting
  • Chu Hopital Lyon Sud
    PierreBenite, France
    Recruiting
  • Hopital Robert Debre
    Reims, France
    Recruiting
  • General Hospital of Athens Alexandra
    Athens, Greece
    Recruiting
  • Irccs Azienda Ospedaliero Universitaria Bologna
    Bologna, Italy
    Recruiting

+22 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.